Loading...
In a recently published, placebo-controlled, randomized trial that involved nearly 4000 insulin-resistant (but not frankly diabetic) patients with recent stroke or transient ischemic attack, pioglitazone lowered risk for cardiovascular events (NEJM JW Gen Med Apr 1 2016 and N Engl J Med 2016; 374:1371). However, fracture incidence was significantly higher in pioglitazone recipients than in placebo recipients — an adverse effect noted in other studies.
In this report, the trial's investigators provide additional detail on fractures:
The estimated 5-year overall incidence of fractures was 13.6% with pioglitazone and 8.8% with placebo.
Pioglitazone, compared with placebo, was associated with significantly higher rates of fall-related fractures (1…